November, 2019

Radboud university medical center and Quirem Medical signed an agreement for joint research. The agreement includes several existing and future projects based on small radioactive spheres (holmium-166 microspheres). Enhanced cooperation should improve the treatment of cancer patients and stimulate research into new applications.

Go to: Highlights

“Radboud university medical center strives for continuous improvement of patient care,” says Professor Jurgen Fütterer, intervention radiologist at Radboud university medical center. “Because we are involved in the development of new treatment techniques, we can tailor these techniques as closely as possible to the needs of the patient. The expansion of our cooperation with Quirem Medical fits in perfectly with that aim.”

Person-oriented treatment

The research into holmium microspheres in Radboudumc takes place in the Radiology and Nuclear Medicine department. The 'nuclear local interventions' are carried out in close cooperation with Jurgen Fütterer and other researchers at the Department of Nuclear Medicine. Fütterer: “Our special MITeC operating theatres enable us to use MRI imaging to show the location of the radioactive holmium spheres during the treatment. This allows treatment that is precisely tailored to the individual.”

Image-guided treatment

Quirem Medical, located in Deventer, is the result of previous innovations by the Nijsen research group. “We have also developed radioactive polylactic acid microspheres for the treatment of liver tumors, called radio embolization,” says Fütterer. "We are now focusing on further refining this image-guided treatment to get an even higher dose into patients' liver tumors. We are also working on similar treatments for pancreatic and brain tumors where we will also apply radiation directly to the tissues themselves. These are developing techniques that Quirem Medical, together with Radboudumc, will try to introduce to the clinic in the coming years."

Working together on innovative applications

Quirem Medical develops and produces holmium-166 microspheres for the treatment of tumors. CEO Jan Sigger: “The radioactive holmium microspheres ensure that the tumors are irradiated locally. Moreover, thanks to the holmium, we can see exactly where the microspheres are and whether there are enough microspheres surrounding the tumor. Our technology is currently being used to treat liver tumors that are no longer operable. Radboudumc offers state-of-the-art research, pre-clinical and clinical facilities that offer excellent opportunities to support and accelerate the development of new applications. The high-quality hot lab facilities in the Radboud Translational Medicine center can also help in the further development of our pipeline of innovative, new applications.”

About Quirem Medical

Quirem Medical is a growing medical device company that is developing the next generation of microspheres for targeted interventional treatment of liver tumors. Quirem Medical is based in Deventer, the Netherlands.